He shares highlights from data announced at the end of the year, and what Janux has learned about the program's dosing and safety mitigation profile. Also, why he has his sights set on the FcRn market when he thinks about the company's CD19.

He describes how the improvement over data from earlier this year gives him confidence in the strength of the signal he sees in this...

David Campbell explains how Janux has used masking technology to improve the profile T-cell engagers in solid tumors.